

ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQSE GROWTH MARKET**APPLICANT NAME:**

Clarify Pharma PLC

APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:

Registered address: 9th Floor 16, Great Queen Street, London, England, WC2B 5DG
Telephone: +44 207 183 7407

DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):

Jonathan Bixby – Executive Chairman
Nicholas James Lyth – Finance Director
Michael Edwards – Non-Executive Director
Jonathan Hives – Independent Non-Executive Director
John Patrick McBride – Non-Executive Director

APPLICANT SECTOR:

Pharmaceuticals and Biotechnology

DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:

Clarify seeks to develop a business concentrating on high potential and fast-growing biotech and life science companies that perform research or produce neuro-pharmaceutical drug development platforms. The focus will be on businesses that advance medicines based on psychedelic substances through rigorous science and clinical trials.

NAME OF AQSE CORPORATE ADVISER:

First Sentinel Corporate Finance Limited

NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:

[TBC] Ordinary Shares of £0.001 par value each are expected to be admitted on Admission.

SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):

TBC

SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT'S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:

Shareholder	No. of shares pre- and post-admission	Holdings – pre-admission	Holdings – post-admission
Marallo Holdings Inc	68,000,000 shares	31.1%	TBC

TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:

N/A

THE EXPECTED ADMISSION DATE:
11 June 2021
WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:
www.clarifypharma.com
<i>In respect of a fast-track applicant, the following information should also be included:</i>
NAME OF MARKET ON WHICH THE APPLICANT'S SECURITIES ARE CURRENTLY TRADED:
N/A
ARRANGEMENTS FOR THE SETTLEMENT OF TRANSACTIONS IN THE APPLICANT'S SECURITIES:
Application will be made for the Ordinary Shares to be admitted to CREST on Admission. Accordingly, settlement of transactions in the Ordinary Shares following Admission may take place within the CREST system if relevant shareholders so wish.
DETAILS OF ANY LOCK-IN ARRANGEMENTS:
The Directors, Timothy Le Druillenec, Marallo Holdings Inc and Olivia Edwards will enter into lock-in agreements, pursuant to which they agree not to dispose of any Ordinary Shares held by them for a period of 12 months from Admission, and to be subject to orderly market arrangements during the six months after the initial one-year lock-in period. In addition, certain shareholders (Ampersand Ventures Ltd, Paniolo Ventures Inc., Caprice Management Pte Ltd, Kuro Ventures Pte Ltd, DFJ Capital and Pallasite Ventures Inc) will enter into lock-in agreements, pursuant to which they agree not to dispose of any Ordinary Shares held by them for a period of 6 months from Admission.
DETAILS OF THE LEGAL OR REGULATORY REQUIREMENTS IN THE APPLICANT'S HOME COUNTRY REGARDING THE CONDUCT OF TAKEOVERS AND THE ACQUISITION OF SIGNIFICANT VOTING RIGHTS TO WHICH THE APPLICANT IS SUBJECT:
N/A
<i>In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:</i>
UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:
27/05/2021